Check out Complete Prescribing Information OPDIVO® (nivolumab) is indicated for that treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which includes relapsed or progressed soon after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or just after 3 or more traces of systemic therapy that includes